NTRB News and Press, Nutriband Inc. From 10/27/25

2025-10-27 07:18:00 ET More on Nutriband Nutriband announces exercise of warrants at $6.43 for gross proceeds of $5.31M Seeking Alpha’s Quant Rating on Nutriband Historical earnings data for Nutriband Financial information for Nutriband Read ...

ORLANDO, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) has announced that Company founder, Gareth Sheridan has returned as Company CEO. During the period of August 10 until October 27 , Co-Founder and Chairman, Serguei Melnik had taken over the responsibil...

2025-10-24 09:09:02 ET Nutriband (NASDAQ: NTRB) , a pharmaceutical company developing transdermal drug delivery technologies, was featured in a Channelchek report by Noble Capital Markets summarizing its presentation at Noble’s Virtual Emerging Growth Conference. The Oct. 23, 202...

2025-10-10 09:05:00 ET Nutriband (NASDAQ: NTRB) , a developer of prescription transdermal pharmaceutical products, announced that its subsidiary 4P Therapeutics has signed an agreement with Brand Institute, Inc., a global leader in pharmaceutical brand name and identity development, to ...

Nutriband initiates commercial worldwide brand name development for its lead product, an abuse deterrent transdermal system. Nutriband has partnered with Brand Institute, Inc, the global leader in pharmaceutical and healthcare-related brand name and identity development. ORLANDO, Fl...

2025-10-09 09:05:00 ET Nutriband (NASDAQ: NTRB) , a developer of prescription transdermal pharmaceutical products, announced the filing of a provisional patent application with the U.S. Patent and Trademark Office to expand protection for its AVERSA(TM) abuse-deterrent transdermal techn...

2025-10-08 12:31:21 ET Nutriband Inc. (NASDAQ: NTRB, NTRBW) , a company specializing in the development of prescription transdermal pharmaceutical products, has announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO). This move aims to ...

Nutriband files provisional patent application to enhance its AVERSA™ transdermal abuse deterrent technology being developed for patches containing opioids and stimulants with a potential for abuse. Nutriband’s AVERSA™ abuse-deterrent technology consists of a prop...

2025-09-25 09:35:00 ET Nutriband (NASDAQ: NTRB) announced it will participate in the MicroCap Rodeo Conference in New York City on Sept. 25, 2025. Company Chairman Serguei Melnik will present at 10 a.m., discussing operational highlights, growth initiatives, and the strategic direction ...

NEW YORK, NY / ACCESS Newswire / September 25, 2025 / The MicroCap Rodeo Conference is live today, featuring presentations from the CEOs and executive management teams of 11 dynamic microcap companies across a wide range of industries. Investors will have the opportunity to hear directly from...